Get to know Sandy Still, PharmD, Bluesight’s newest Director of Clinical Strategy
Get to know Sandy Still, PharmD, Bluesight’s newest Director of Clinical Strategy
Sandy Still, PharmD, joins Bluesight as the newest Director of Clinical Strategy. Sandy is a…
What Does ASHP’s Revised Drug Diversion Guidelines Mean for Your Hospital?
What Does ASHP’s Revised Drug Diversion Guidelines Mean for Your Hospital? By: Sandy Still, PharmD…
Why a Next-Generation Drug Diversion Solution is Vital for Hospitals.
By: Doug Zurawski, Pharm.D. Drug diversion is any act or deviation that removes a…
The Pandemic’s Continued Strain On Labor And Other Key Takeaways From The Diversion Trends Report
Kit Check recently released its 2022 Diversion Trends Report. In the report, Kit Check analyzed…
5 Signs That You May Need Outside Help with Your Drug Diversion Program
Every hospital today is in some stage of planning, implementing and/or managing a drug diversion…
Diversion Quarterly — Q3 2020
Kit Check is sharing data from its Bluesight™ for Controlled Substances platform on a quarterly…
Doug Zurawski in Pharmacy Times – Enter AI: How Technology is Changing the Pharmaceutical Industry for the Better
Doug Zurawski, Senior Vice President of Clinical Strategy at Kit Check, was recently published in…
Nursing during COVID-19: A Chat with AJ Rivosecchi and Carol Purcell
Kit Check’s Senior Director of Clinical Strategy AJ Rivosecchi sat down (virtually) with Carol Purcell,…
Webinar Recording: Current Perspectives and Future Trends in Diversion Detection Webinar
Recently we hosted an online symposium around the topic of diversion detection. We were honored …
Kit Check Presents Groundbreaking Drug Diversion Symposium Featuring Top Industry Leaders
Continuing education webinar addresses critical components, perspectives and best practices for hospitals, pharmacists and medical …